Allogene Therapeutics, Inc (ALLO) insider trading
Every open-market stock purchase and sale by Allogene Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $603K over the last 12 months (14 sales). No open-market buys.
- Last insider buy: Arie Belldegrun (Director), $5M, 2 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $603K (14 sales). Last close $2.12 on Jul 8, 2026.
Recent ALLO insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jul 1, 2026 | Zachary Roberts (CEO) | Bought (not open market) | — |
| Jul 1, 2026 | Zachary Roberts (CEO) | Bought (not open market) | — |
| Jun 18, 2026 | Joshua A Kazam (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Joshua A Kazam (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Franz B Humer (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Stephen Mayo (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Deborah M. Messemer (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Elizabeth A. Barrett (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Owen N. Witte (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Vicki L Sato (Director) | Bought (not open market) | — |
| Apr 21, 2026 | Annie Yoshiyama (VP) | Sold | $22.1K |
| Mar 31, 2026 | Benjamin Machinas Beneski (CTO) | Sold | $7.2K |
| Mar 16, 2026 | David D Chang (CEO) | Sold | $118K |
| Mar 16, 2026 | Benjamin Machinas Beneski (CTO) | Sold | $11.9K |
| Mar 2, 2026 | Benjamin Machinas Beneski (CTO) | Sold | $18.5K |
| Feb 2, 2026 | David D Chang (CEO) | Sold | $171K |
| Feb 2, 2026 | Zachary Roberts (VP) | Sold | $63.2K |
| Feb 2, 2026 | Geoffrey M. Parker (CFO) | Sold | $42.2K |
| Feb 2, 2026 | Earl Martin Douglas (VP) | Sold | $40.3K |
| Feb 2, 2026 | Benjamin Machinas Beneski (CTO) | Sold | $13.1K |
| Feb 2, 2026 | Annie Yoshiyama (VP) | Sold | $7.2K |
| Feb 2, 2026 | Benjamin Machinas Beneski (CTO) | Bought (not open market) | — |
| Feb 2, 2026 | Earl Martin Douglas (VP) | Bought (not open market) | — |
| Feb 2, 2026 | Earl Martin Douglas (VP) | Bought (not open market) | — |
| Feb 2, 2026 | Zachary Roberts (VP) | Bought (not open market) | — |
Who's trading ALLO
- Zachary Roberts, VP: sold $104K (2 sales), last Jul 1, 2026
- Elizabeth A. Barrett, Director: other filings, last Jun 18, 2026
- Franz B Humer, Director: other filings, last Jun 18, 2026
- Joshua A Kazam, Director: other filings, last Jun 18, 2026
- Deborah M. Messemer, Director: other filings, last Jun 18, 2026
- Stephen Mayo, Director: other filings, last Jun 18, 2026
- Vicki L Sato, Director: other filings, last Jun 18, 2026
- Owen N. Witte, Director: other filings, last Jun 18, 2026
- Annie Yoshiyama, VP: sold $29.3K (2 sales), last Apr 21, 2026
- Benjamin Machinas Beneski, CTO: sold $51.7K (5 sales), last Mar 31, 2026
- David D Chang, CEO: sold $289K (2 sales), last Mar 16, 2026
- Earl Martin Douglas, VP: sold $40.3K (1 sale), last Feb 2, 2026
- Arie Belldegrun, Director: other filings, last Feb 2, 2026
- Geoffrey M. Parker, CFO: sold $88.4K (2 sales), last Feb 2, 2026
Get free alerts when an insider at Allogene Therapeutics, Inc files a new trade →